

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
05 May 2022 (05.05.2022)



(10) International Publication Number  
**WO 2022/090169 A1**

(51) International Patent Classification:

C07K 16/18 (2006.01) A61P 25/28 (2006.01)  
A61P 25/00 (2006.01) G01N 33/68 (2006.01)  
A61P 25/16 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/EP2021/079566

(22) International Filing Date:

25 October 2021 (25.10.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/105,810 26 October 2020 (26.10.2020) US  
63/250,114 29 September 2021 (29.09.2021) US

(71) Applicant: JANSSEN PHARMACEUTICA NV  
[BE/BE]; Turnhoutseweg 30, 2340 Beerse (BE).

(72) Inventors: HENLEY, David; 630 Teetor Rd, Hagerstown,  
IN 47346 (US). NANDY, Partha; 920 Route 202 South,  
Raritan, New Jersey 08869 (US). RUIXO, Carlos Pérez;  
P.º Doce Estrellas, 5, 28042 Madrid (ES).

(74) Agent: DUFFIELD, Stephen et al.; Carpmacels & Ransford  
LLP, One Southampton Row, London WC1B 5HA (GB).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHOD OF SAFE ADMINISTRATION OF ANTI-TAU ANTIBODY




Figure 1

(57) Abstract: Methods are described for safely administering to a subject in need thereof an anti-tau antibody that bind to tau, in particular that bind to a phosphorylated epitope on tau. The methods comprise administering a pharmaceutical composition comprising the anti-tau antibody, in which the anti-tau antibody is administered in an amount of about 500 mg to 5000 mg per dose.

[Continued on next page]

**Published:**

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*